In B16F10 melanoma mouse models, SON-1210 demonstrated superior efficacy compared to native cytokines, significantly reducing tumor growth and enhancing immune responses, including elevated IFNγ levels and increased Th1 and CTL cell counts. This evidence concerns the gene IFNG and neoplasm.